Synthesis, physicochemical and in vitro pharmacological investigation of new platinum (II) complexes with some cycloalkanespiro-5′-hydantoins

被引:22
作者
Bakalova, A
Buyukliev, R
Momekov, G
Ivanov, D
Todorov, D
Konstantinov, S
Karaivanova, M
机构
[1] Med Univ Sofia, Fac Pharm, Dept Pharmacol & Toxicol, Lab Expt Chemotherapy, Sofia 1000, Bulgaria
[2] Med Univ Sofia, Dept Chem, Fac Pharm, Sofia 1000, Bulgaria
[3] Med Univ Sofia, Fac Pharm, Dept Organ Chem, Sofia 1000, Bulgaria
[4] Natl Oncol Ctr, Lab Oncopharmacol, Sofia 1756, Bulgaria
关键词
Pt(II) complexes; hydantoins; cytotoxicity; nephrotoxicity;
D O I
10.1016/j.ejmech.2005.01.009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Platinum (II) complexes with cyclobutanespiro-5'-hydantoin and cycloheptanespiro-5'-hydantoin were synthesized and evaluated by means of general physicochemical methods. The data from the elemental analysis, IR and NMR spectra suggested the formation of cis-[Pt(C6H8N2O2)(2)(NH3)(2)](NO3)(2)center dot 4H(2)O (PtCBH), when cyclobutanespiro-5'-hydantoin was used as a ligand and cis-[Pt(C9H14N2O2)-(NH3)(2)](NO3)(2)center dot 4H(2)O (PtCHTH), when cycloheptanespiro-5'-hydantoin was used, respectively. The novel complexes exerted cytotoxic effects at micromolar concentrations against a panel of human tumor cell lines. They were found to trigger apoptosis in HL-60 and BV-173 cells as evidenced by DNA-laddering detection. The evaluation of the effects of PtCBH, PtCHTH and the antineoplastic drugs cisplatin and oxaliplatin against cultured murine kidney epithelial cells revealed that the hydantoin complexes were far less nephrotoxic in vitro. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码:590 / 596
页数:7
相关论文
共 18 条
[1]  
Akiyama S, 1999, ANTI-CANCER DRUG DES, V14, P143
[2]  
Amtmann E, 2001, CANCER CHEMOTH PHARM, V47, P461
[3]   Synthesis, physicochemical investigation and cytotoxic activity of new Pt(II) complexes with hydantoin ligands [J].
Bakalova, A ;
Buyukliev, R ;
Tcholakova, I ;
Momekov, G ;
Konstantinov, S ;
Karaivanova, M .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (06) :627-632
[4]  
BOKEMEYER C, 1996, KOMPENDIUM INT ONKOL, P1131
[5]  
Boulikas T, 2003, ONCOL REP, V10, P1663
[6]  
Canal P, 1998, CLINICIAN'S GUIDE TO CHEMOTHERAPY PHARMACOKINETICS AND PHARMACODYNAMICS, P345
[7]  
CLEARE M, 1979, Patent No. 41470707
[8]   Particular aspects of platinum compounds used at present in cancer treatment [J].
Desoize, B ;
Madoulet, C .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 42 (03) :317-325
[9]  
Freshney RI., 1999, FRESHNEYS CULTURE AN
[10]  
Hanigan Marie H, 2003, Cancer Ther, V1, P47